Experience with the Use of B-RAF Inhibitor Vemurafenib in the Treatment of Hairy Cell Leukemia

AUTOIMMUNE THROMBOCYTOPENIA

LS Al-Radi, SYu Smirnova, TN Moiseeva, IS Piskunova, LV Plastinina, DV Novikova, EG Gemdzhian, GM Galstyan

National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167

For correspondence: Svetlana Yurevna Smirnova, MD, PhD, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167; Tel.: +7(926)879-65-94; e-mail: smirnova-s-ju@yandex.ru

For citation: Al-Radi LS, Smirnova SYu, Moiseeva TN, et al. Experience with the Use of B-RAF Inhibitor Vemurafenib in the Treatment of Hairy Cell Leukemia. Clinical oncohematology. 2022;15(4):349–55. (In Russ).

DOI: 10.21320/2500-2139-2022-15-4-349-355

ABSTRACT

Background. The standard and effective treatment of hairy cell leukemia (HCL) involves purine analogs, interferon-α (IFN-α) administration, and splenectomy. However, primary resistant HCL and early relapses (within 2–3 years after achieving remission) remain clinical challenges. Due to myelotoxicity of cladribine and slow effect of IFN-α, these drugs can be administered neither in deep neutropenia/agranulocytosis patients (especially in case of infectious complications) nor in patients with IFN-α allergy/intolerance.

Aim. To report clinical experience with vemurafenib, a B-RAF inhibitor, in HCL with BRAFV600E mutation in treatment-resistant patients with contraindications to standard therapy.

Materials & Methods. The study enrolled 39 HCL patients aged 24–78 years (median 55 years), 13 women and 26 men. HCL was diagnosed in accordance with the WHO 2017 criteria. Vemurafenib 240 mg was administered once or twice a day within 3 months. Three groups of patients were analyzed: those with early relapses and resistant HCL (n = 7), those with deep neutropenia/agranulocytosis (with and without infectious complications, n = 29), and those with IFN-α intolerance (n = 3).

Results. In 6 (86 %) out of 7 patients from group 1 (with early relapses and resistant HCL) a complete course of treatment was carried out, which included vemurafenib with subsequent standard cladribine chemotherapy and further consolidation with rituximab. Complete remission was achieved in 5 (71 %) patients, and partial remission was achieved in 1 (14 %) patient. The 7th patient was a non-responder. In 28 (97 %) out of 29 patients from group 2 with deep neutropenia/agranulocytosis, hematologic recovery was reported which allowed for further basic treatment with cladribine. In 1 patient vemurafenib appeared to be ineffective. In 3 patients from group 3 with IFN-α intolerance, vemurafenib administration was used as a stage of treatment preceding cladribine therapy. Cladribine treatment resulted in complete remission in 2 (67 %) patients and partial remission in 1 (33 %) patient.

Conclusion. In HCL with BRAFV600E mutation, low-dose vemurafenib can be effective in patients with relapsed/refractory disease as well as deep neutropenia with life-threatening infectious complications. In addition to that, vemurafenib administration can be used in cases of IFN-α intolerance as a stage of treatment of HCL with BRAFV600E mutation which precedes the basic cladribine therapy.

Keywords: hairy cell leukemia, B-RAF inhibitor, vemurafenib, relapsed/refractory disease, agranulocytosis, infectious complications.

Received: April 25, 2022

Accepted: September 2, 2022

Read in PDF

Статистика Plumx английский

REFERENCES

  1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90. doi: 10.1182/blood-2016-01-643569.
  2. Grever MR. How I treat hairy cell leukemia. Blood. 2010;115(1):21–8. doi: 10.1182/blood-2009-06-195370.
  3. Алгоритмы диагностики и протоколы лечения заболеваний системы крови. Под ред. В.Г. Савченко. М.: Практика, 2018. Т. 2. С. 363–84.
    [Savchenko VG, ed. Algoritmy diagnostiki i protokoly lecheniya zabolevanii sistemy krovi. (Diagnostic algorithms and treatment protocols in hematological diseases.) Moscow: Praktika; 2018. Vol. 2. pр. 363–84. (In Russ)]
  4. Аль-Ради Л.С. Волосатоклеточный лейкоз: особенности течения, современная тактика терапии: Дис.… канд. мед. наук. М., 2008.
    [Al-Radi LS. Volosatokletochnyi leikoz: osobennosti techeniya, sovremennaya taktika terapii. (Hairy cell leukemia: clinical features, current treatment strategy.) [dissertation] Moscow; 2008. (In Russ)]
  5. Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med. 1990;322(16):1117–21. doi: 10.1056/NEJM199004193221605.
  6. Tallman MS, Hakimian D, Variakojis D, et al. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood. 1992;80(9):2203–9.
  7. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364(24):2305–15. doi: 10.1056/NEJMoa1014209.
  8. Grever MR, Abdel-Wahab O, Andritsos LA, et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood. 2017;129(5):553–60. doi: 10.1182/blood-2016-01-689422.
  9. Tiacci E, Schiavoni G, Martelli MP, et al. Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia. Haematologica. 2013;98(9):635–9. doi: 10.3324/haematol.2012.078071.
  10. Урнова Е.С., Аль-Ради Л.С., Кузьмина Л.А. и др. Успешное применение вемурафениба у больного с резистентной формой волосатоклеточного лейкоза. Терапевтический архив. 2013;85(7):76–8.
    [Urnova ES, Al’-Radi LS, Kuz’mina LA, et al. Successful use of vemurafenib in a patient with resistant hairy cell leukemia. Terapevticheskii arkhiv. 2013;85(7):76–8. (In Russ)]
  11. Dietrich S, Zenz T. BRAF inhibitor therapy in HCL. Best Pract Res Clin Haematol. 2015;28(4):246–52. doi: 10.1016/j.beha.2015.10.001.
  12. Fiskus W, Mitsiades N. B-Raf inhibition in the clinic: present and future. Annu Rev Med. 2016;67(1):29–43. doi: 10.1146/annurev-med-090514-030732.
  13. Dietrich S, Glimm H, Andrulis M, et al. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med. 2012;366(21):2038–40. doi: 10.1056/NEJMc1202124.
  14. Shallis RM, Patel TH, Podoltsev NA, et al. Disseminated, yet dissembled: Rare infections behind the veil of classical hairy cell leukemia. Leuk Res. 2020;90:106315. doi: 10.1016/j.leukres.2020.106315.
  15. Maurer H, Haas P, Wengenmayer T, et al. Successful vemurafenib salvage treatment in a patient with primary refractory hairy cell leukemia and pulmonary aspergillosis. Ann Hematol. 2014;93(8):1439–40. doi: 10.1007/s00277-013-1987-7.
  16. Peyrade F, Re D, Ginet C, et al. Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E Haematologica. 2013;98(2):e20–e22. doi: 10.3324/haematol.2012.082404.
  17. Robak T, Wolska A, Robak P. Potential breakthroughs with investigational drugs for hairy cell leukemia. Expert Opin Investig Drugs. 2015;24(11):1419–31. doi: 10.1517/13543784.2015.1081895.
  18. Jain P, Polliack A, Ravandi F. Novel therapeutic options for relapsed hairy cell leukemia. Leuk Lymphoma. 2015;56(8):2264–72. doi: 10.3109/10428194.2014.1001988.
  19. Sarvaria A, Topp Z, Saven A. Current therapy and new directions in the treatment of hairy cell leukemia: a review. JAMA Oncol. 2016;2(1):123–9. doi: 10.1001/jamaoncol.2015.4134.
  20. Dearden CE, Else M, Catovsky D. Long-term results for pentostatin and cladribine treatment of hairy cell leukemia. Leuk Lymphoma. 2011;52(Suppl 2):21–4. doi: 10.3109/10428194.2011.565093.
  21. Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol. 2003;21(5):891–6. doi: 10.1200/JCO.2003.05.093.
  22. Tadmor T. Purine Analog Toxicity in Patients With Hairy Cell Leukemia. Leuk Lymphoma. 2011;52(Suppl 2):38–42. doi: 10.3109/10428194.2011.565097.
  23. Epperla N, Pavilack M, Olufade T, et al. Adverse event rates and economic burden associated with purine nucleoside analogs in patients with hairy cell leukemia: a US population-retrospective claims analysis. Orphanet J of Rare Dis. 2020;15(1):47. doi: 10.1186/s13023-020-1325-9.
  24. Dasanu CA, Ichim TE, Alexandrescu DT. Inherent and iatrogenic immune defects in hairy cell leukemia: revisited. Expert Opin Drug Saf. 2010;9(1):55–9. doi: 10.1517/14740330903427951.
  25. Golomb HM, Hadad LJ. Infectious complications in 127 patients with hairy cell leukemia. Am J Hematol 1984;16(4):393–401. doi: 10.1002/ajh.2830160410.
  26. Kraut E. Infectious complications in hairy cell leukemia. Leuk Lymphoma. 2011;52(Suppl 2):50–2. doi: 10.3109/10428194.2011.570819.
  27. Damaj G, Kuhnowski F, Marolleau JP, et al. Risk factors for severe infections in patients with hairy cell leukemia: a long-term study of patients. Eur J Haematol. 2009;83(3):246–50. doi: 10.1111/j.1600-0609.2009.01259.x.
  28. Аль-Ради Л.С., Моисеева Т.Н., Смирнова С.Ю., Шмаков Р.Г. Волосатоклеточный лейкоз и беременность. Терапевтический архив. 2017;89(7):99–104.
    [Al’-Radi LS, Moiseeva TN, Smirnova SYu, Shmakov RG. Hairy cell leukemia and pregnancy. Terapevticheskii arkhiv. 2017;89(7):99–104. (In Russ)]
  29. Волкова М.А. Волосатоклеточный лейкоз. В кн.: Клиническая онкогематология. Руководство для врачей, 2-е изд. Под ред. М.А. Волковой. М.: Медицина, 2007. С. 819–34.
    [Volkova MA. Hairy cell leukemia. In: Volkova MA, ed. Klinicheskaya onkogematologiya. Rukovodstvo dlya vrachei. (Clinical oncohematology. A physician’s manual.) 2nd edition. Moscow: Meditsina Publ.; 2007. pр. 819–34. (In Russ)]
  30. Bohn JP, Gastl G, Steurer M. Long-term treatment of hairy cell leukemia with interferon-α: still a viable therapeutic option. MEMO. 2016;9:63–5. doi: 10.1007/s12254-016-0269-1.
  31. Аль-Ради Л.С., Пивник А.В. Особенности течения и современная тактика терапии волосатоклеточного лейкоза. Клиническая онкогематология. 2009;2(2):111–20.
    [Al’-Radi LS, Pivnik AV. Clinical features and current strategy of hairy cell leukemia treatment. Klinicheskaya onkogematologiya. 2009;2(2):111–20. (In Russ)]
  32. Thompson J, Tallman MS, Pulliack A. Past and present role of interferon in hairy cell leukemia. In: Tallmlan MS, Pulliack A, eds. Advances in Blood Disorders. Vol. 5. UK: Harwood academic Publishers; 2000. рр. 127–39.
  33. Скопец А.А., Корнилов И.А., Афонин Е.С. Роль экстракорпоральной мембранной оксигенации в терапии легионеллезной пневмонии у пациентки с волосатоклеточным лейкозом. Инновационная медицина Кубани. 2019;(3):44–8. doi: 10.35401/2500-0268-2019-15-3-44-48.
    [Skopets AA, Kornilov IA, Afonin ES. Importance of extracorporeal membrane oxygenation (ECMO) in therapy for legionella pneumonia in patient with hairy-cell leucosis. Innovative Medicine of Kuban. 2019;(3):44–8. doi: 10.35401/2500-0268-2019-15-3-44-48. (In Russ)]
  34. Галстян Г.М., Баженов А.В., Данишян К.И. и др. Роль спленэктомии в лечении острой дыхательной недостаточности у больной волосатоклеточным лейкозом. Гематология и трансфузиология. 2017;62(1):51–4.
    [Galstyan GM, Bazhenov AV, Danishyan KI, et al. The role of splenectomy in the treatment of acute respiratory distress in a female patient with hairy cell leukemia. Gematologiya i transfuziologiya. 2017;62(1):51–4. (In Russ)]
  35. Smirnova SY, Al-Radi LS, Moiseeva TN, et al. Inhibitor of BRAF(V600E) mutation as a treatment option for hairy cell leukemia with deep neutropenia and infectious complications. Clin Lymphoma Myeloma Leuk. 2021;21(7):427–30. doi: 10.1016/j.clml.2021.02.005
  36. Tiacci E, Park JH, De Carolis L, et al. Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. N Engl J Med. 2015;373(18):1733–47. doi: 10.1056/NEJMoa1506583.
  37. Tiacci E, De Carolis L, Simonetti E, et al. Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia. N Engl J Med. 2021;384(19):1810–23. doi: 10.1056/NEJMoa2031298.
  38. Bohn JP, Pircher A, Wanner D, et al. Low-dose Vemurafenib in hairy cell leukemia patients with active infection. Am J Hematol. 2019;94(6):E180–E182. doi: 10.1002/ajh.25474.
  39. Shenoi DP, Andritsos AL, Blachly JS. Classic hairy cell leukemia complicated by pancytopenia and severe infection: a report of 3 cases treated with vemurafenib. Blood Adv. 2019;3(2):116–8. doi: 10.1182/bloodadvances.2018027466.
  40. Dietrich S, Hullein S, Hundemer M, et al. Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia. J Clin Oncol. 2013;31(19):e300–e303. doi: 10.1200/JCO.2012.45.9495.
  41. Robert C, Arnault JP, Mateus C. RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol. 2011;23(2):177–82. doi: 10.1097/CCO.0b013e3283436e8c.
  42. Zimmer L, Hillen U, Livingstone E, et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol. 2012;30(19):2375–83. doi: 10.1200/JCO.2011.41.1660.